【摘要】：目的觀察參麥注射液對(duì)胸外科手術(shù)患者預(yù)后的臨床療效及安全性。方法將48例胸外科手術(shù)患者隨機(jī)分為對(duì)照組24例和試驗(yàn)組24例。對(duì)照組于圍手術(shù)期給予常規(guī)治療;試驗(yàn)組在對(duì)照組治療的基礎(chǔ)上,于麻醉誘導(dǎo)后予以靜脈滴注參麥注射液50 mL qd,連續(xù)給藥5 d。比較2組患者術(shù)前和術(shù)后1,4,48,120 h血清白細(xì)胞介素-6(IL-6)、IL-8、補(bǔ)體C_3、C_4的變化、免疫功能,以及藥物不良反應(yīng)的發(fā)生情況。結(jié)果術(shù)后1,4,48,120 h,試驗(yàn)組的IL-6分別為(124.58±29.12),(90.26±15.83),(29.17±4.21)和(16.53±2.02)pg·mL~(-1),對(duì)照組的IL-6分別為(398.56±56.22),(239.68±34.23),(148.52±18.93)和(96.43±14.63)pg·mL~(-1);試驗(yàn)組的IL-8分別為(16.19±5.24),(9.26±3.13),(4.38±1.42)和(3.43±1.14)pg·mL~(-1),對(duì)照組的IL-8分別為(24.57±6.33),(19.79±3.17),(148.52±18.92)和(96.4±14.63)pg·mL~(-1),2組術(shù)后各時(shí)點(diǎn)的IL-6和IL-8比較,差異均有統(tǒng)計(jì)學(xué)意義(均P0.05)。術(shù)前和術(shù)后1,4,48,120 h,試驗(yàn)組的補(bǔ)體C_3分別為(1.12±0.47)%,(0.85±0.22)%,(0.80±0.26)%,(0.78±0.19)%和(0.77±0.14)%,對(duì)照組的補(bǔ)體C_3分別為(1.10±0.47)%,(0.61±0.28)%,(0.76±0.24)%,(0.83±0.21)%和(0.81±0.16)%;試驗(yàn)組的補(bǔ)體C_4分別為(0.49±0.27)%,(0.31±0.16)%,(0.35±0.14)%,(0.36±0.17)%和(0.35±0.15)%,對(duì)照組的補(bǔ)體C_4分別為(0.51±0.28)%,(0.37±0.21)%,(0.32±0.18)%,(0.39±0.14)%和(0.37±0.16)%,且2組術(shù)后各時(shí)點(diǎn)的補(bǔ)體C_3和C_4水平與術(shù)前比較,差異均有統(tǒng)計(jì)學(xué)意義(均P0.05)。術(shù)前和術(shù)后1,4,48,120 h,試驗(yàn)組的CD_3~+分別為(69.87±2.34)%,(60.49±2.18)%,(54.17±1.78)%,(52.46±1.79)%和(51.41±1.79)%,對(duì)照組的CD_3~+分別為(70.12±2.47)%,(53.18±2.19)%,(52.52±1.79)%,(50.79±2.09)%和(50.31±1.72)%;試驗(yàn)組的CD_4~+分別為(43.04±3.85)%,(35.46±2.56)%,(32.17±1.98)%,(29.59±2.14)%和(29.21±2.11)%,對(duì)照組的CD_4~+分別為(42.93±2.51)%,(32.73±2.28)%,(30.41±2.04)%,(31.14±1.89)%和(30.57±2.16)%;試驗(yàn)組的CD_4~+/CD_8~+分別為(1.57±0.39),(1.40±0.41),(1.39±0.37),(1.37±0.35)和(1.38±0.36),對(duì)照組的CD_4~+/CD_8~+分別為(1.56±0.43),(1.24±0.29),(1.33±0.25),(1.36±0.28)和(1.39±0.34),且2組患者術(shù)后各時(shí)點(diǎn)的CD_3~+、CD_4~+、CD_4~+/CD_8~+水平與術(shù)前比較,差異均有統(tǒng)計(jì)學(xué)意義(均P0.05)。2組患者治療過程中未出現(xiàn)嚴(yán)重藥物不良反應(yīng)。結(jié)論參麥注射液可明顯提高胸外科患者術(shù)后的恢復(fù)效果,降低患者的炎癥因子和補(bǔ)體C_3、C_4水平,改善患者的免疫功能,且安全性較高。
[Abstract]:Objective to observe the clinical effect and safety of Shenmai injection on the prognosis of patients undergoing thoracic surgery. Methods 48 patients undergoing thoracic surgery were randomly divided into control group (n = 24) and experimental group (n = 24). The control group was given routine treatment during perioperative period, and the experimental group was treated with Shenmai injection 50 mL QD intravenous drip for 5 days after anesthesia induction on the basis of the treatment in the control group. The changes of serum interleukin-6 (IL-6) and interleukin-6 (IL-6) IL-8, complement C _ 3O _ C _ 4, immune function and adverse drug reactions were compared between the two groups before and after operation. 緇撴灉鏈悗1,4,48,120 h,璇曢獙緇勭殑IL-6鍒嗗埆涓，

本文編號(hào)：2138064